

Stefano Sacchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7938317/publications.pdf>

Version: 2024-02-01

120
papers

2,779
citations

230014

27
h-index

232693

48
g-index

121
all docs

121
docs citations

121
times ranked

3653
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting. <i>Leukemia Research</i> , 2021, 104, 106552.	0.4	4
2	Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7652.	1.8	33
3	The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments. <i>Annals of Hematology</i> , 2020, 99, 277-282.	0.8	11
4	Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2020, 25, 370-387.	2.2	17
5	Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 439-445.	0.8	4
6	Preclinical Efficacy and Biological Effects of Venetoclax and Ixazomib in Combination in Lymphoma Cells. <i>Blood</i> , 2020, 136, 37-38.	0.6	1
7	The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1958-1964.	0.6	4
8	Absolute monocyte count at diagnosis could improve the prognostic role of early ¹⁸F-FDG PET in classical Hodgkin lymphoma patients. <i>British Journal of Haematology</i> , 2018, 180, 600-602.	1.2	2
9	Cell-Penetrating CaCO ₃ Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma. <i>Cancers</i> , 2018, 10, 31.	1.7	13
10	Combination of Momelotinib and Citarinostat Show Strong Synergistic Effect in Lymphoid Cell Lines Co-Targeting JAK2/STAT3 and HDAC6. <i>Blood</i> , 2018, 132, 3506-3506.	0.6	0
11	Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2017, 22, 827-840.	2.2	44
12	A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up. <i>Acta Haematologica</i> , 2017, 137, 7-14.	0.7	4
13	Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. <i>Leukemia and Lymphoma</i> , 2017, 58, 552-559.	0.6	9
14	Neutrophil-to-Lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosing Hodgkin lymphoma: results of a large multicenter study involving 990 patients. <i>Hematological Oncology</i> , 2017, 35, 561-566.	0.8	36
15	Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases. <i>Oncotarget</i> , 2017, 8, 103797-103814.	0.8	17
16	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e196-e199.	1.7	15
17	The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines. <i>Cancer Biology and Therapy</i> , 2016, 17, 1094-1106.	1.5	25
18	The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines. <i>Hematological Oncology</i> , 2015, 33, 166-175.	0.8	15

#	ARTICLE	IF	CITATIONS
19	Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study. <i>Journal of Breast Cancer</i> , 2015, 18, 378.	0.8	25
20	Activity of BKM120 and BEZ235 against Lymphoma Cells. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	13
21	Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients. <i>Mayo Clinic Proceedings</i> , 2015, 90, 756-764.	1.4	39
22	Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery. <i>Blood</i> , 2015, 126, 4851-4851.	0.6	0
23	LONG-TERM Outcome of a Fondazione Italiana Linfomi Study Comparing Short Rituximab Maintenance Vs Observation after Brief First-LINE R-FND Chemoimmunotherapy Followed By Rituximab Consolidation in Elderly Patients with Advanced Follicular Lymphoma (FL). <i>Blood</i> , 2015, 126, 3985-3985.	0.6	0
24	Neutrophil - Lymphocyte Ratio (NLR) at Diagnosis Is an Independent Prognostic Factor in Patients with Nodular Sclerosis Hodgkin Lymphoma: Results of a Large Multicenter Study Involving 990 Patients. <i>Blood</i> , 2015, 126, 3862-3862.	0.6	0
25	Neutrophil to Lymphocyte Ratio at Diagnosis Is an Independent Prognostic Factor in Diffuse Large B-Cell Lymphoma: Results of a Large Multicenter Study Involving 931 Patients. <i>Blood</i> , 2015, 126, 1465-1465.	0.6	0
26	The potential of pralatrexate as a treatment of peripheral T-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 711-718.	1.9	3
27	Dialysisâ€dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma â€ response to <sc>M</sc>urphy <i>etÂal</i>. <i>British Journal of Haematology</i> , 2014, 165, 892-892.	1.2	1
28	Defining the best cutâ€off value for lymphopenia in diffuse large B cell lymphoma treated with immunoâ€chemotherapy. <i>British Journal of Haematology</i> , 2014, 167, 133-136.	1.2	6
29	Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. <i>Haematologica</i> , 2014, 99, 125-130.	1.7	77
30	Prognostic Role of Serum Albumin Level in DLBCL before and during the Rituximab Era. Retrospective GISL Study over 738 Cases. <i>Blood</i> , 2014, 124, 5411-5411.	0.6	0
31	New Targets and Potential Strategy to Enhance the Anticancer Efficacy BKM-120 and BEZ235 in Lymphoma Cell Lines. <i>Blood</i> , 2014, 124, 1773-1773.	0.6	2
32	Prognostic Score Based on Clinical and Biochemical Surrogates of Disease Status in DLBCL Trated with Chemo-Immunotherapy. <i>Blood</i> , 2014, 124, 3027-3027.	0.6	0
33	Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. <i>Leukemia Research</i> , 2013, 37, 619-623.	0.4	24
34	Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75Âyears: a population-based analysis. <i>British Journal of Haematology</i> , 2013, 163, 40-46.	1.2	80
35	R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLLO5 Trial Conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 1506-1513.	0.8	223
36	Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 4383-4383.	0.6	1

#	ARTICLE	IF	CITATIONS
37	NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy. Expert Opinion on Investigational Drugs, 2012, 21, 1597-1606.	1.9	14
38	Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines. Annals of Hematology, 2012, 91, 1613-1622.	0.8	8
39	Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia. Cancer, 2012, 118, 434-443.	2.0	97
40	In Vitro Combination of Bortezomib with Enzastaurin or Lenalidomide Enhances the Cytotoxicity in B-Cell Lymphoma Cell Lines.. Blood, 2012, 120, 2754-2754.	0.6	1
41	R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL).. Journal of Clinical Oncology, 2012, 30, 8006-8006.	0.8	5
42	PCR-Based Minimal Residual Disease (MRD) Detection Is a Strong Independent Outcome Predictor Also in Rituximab-Intensive Non-ASCT-Based Programs: Results From the ML17638 Multicenter Randomised Phase III Trial for Elderly Follicular Lymphoma (FL) Patients of the Fondazione Italiana Linfomi (FIL). Blood, 2012, 120, 787-787.	0.6	0
43	Monocytosis Has Adverse Prognostic Significance and Impacts Survival in Patients with T-Cell Lymphomas.. Blood, 2012, 120, 2647-2647.	0.6	0
44	Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma. Expert Opinion on Investigational Drugs, 2011, 20, 1029-1031.	1.9	7
45	A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. Leukemia and Lymphoma, 2011, 52, 1942-1948.	0.6	28
46	Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. Annals of Oncology, 2011, 22, 1845-1858.	0.6	76
47	Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leukemia and Lymphoma, 2011, 52, 771-775.	0.6	86
48	Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2011, 52, 1867-1872.	0.6	43
49	THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011065.	0.5	15
50	Relative Survival and Incidence Based Mortality of Diffuse Large B-Cell Lymphoma (DLBCL) in Rituximab Era: Population Based Study From Modena Cancer Registry (MCR). Blood, 2011, 118, 5185-5185.	0.6	0
51	Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. Leukemia Research, 2010, 34, e217-e218.	0.4	3
52	Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Annals of Oncology, 2010, 21, 1486-1491.	0.6	79
53	Effects of enzastaurin, alone or in combination, on signaling pathway controlling growth and survival of B-cell lymphoma cell lines. Leukemia and Lymphoma, 2010, 51, 671-679.	0.6	14
54	Phase II Study of Velcade® Plus Mabthera® In Relapsed Follicular Lymphomas. Blood, 2010, 116, 1801-1801.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Combination of Enzastaurin, a PKC Inhibitor, and Revlimid [®] has Synergistic Activity In Non-Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 4905-4905.	0.6	1
56	Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial. <i>Blood</i> , 2010, 116, 1360-1360.	0.6	2
57	Interferon: Does it still have a role in the 21st century?. <i>Leukemia and Lymphoma</i> , 2009, 50, 1562-1563.	0.6	2
58	Molecular targeting of the PKC inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression. <i>Hematological Oncology</i> , 2009, 27, 23-30.	0.8	20
59	Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. <i>Cancer</i> , 2009, 115, 1906-1913.	2.0	6
60	Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies.. <i>Blood</i> , 2009, 114, 1918-1918.	0.6	0
61	Role of thalidomide in previously untreated patients with multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1569-1580.	1.1	4
62	Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. <i>Haematologica</i> , 2008, 93, 398-404.	1.7	92
63	The oral protein-kinase C inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. <i>Leukemia and Lymphoma</i> , 2008, 49, 1374-1383.	0.6	37
64	Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study. <i>Haematologica</i> , 2008, 93, 1335-1342.	1.7	35
65	Effects of Enzastaurin, Alone or in Combination, on Signalling Pathway Controlling Growth and Survival of B-Cell Lymphoma Cell Lines. <i>Blood</i> , 2008, 112, 4978-4978.	0.6	0
66	Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2007, 48, 56-64.	0.6	86
67	Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. <i>Cancer</i> , 2007, 109, 2077-2082.	2.0	50
68	Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. <i>Cancer</i> , 2007, 110, 121-128.	2.0	41
69	Incidence and Outcome of Myelodysplastic Syndromes in Province of Modena.. <i>Blood</i> , 2007, 110, 4610-4610.	0.6	1
70	Incidence and Outcome of Chronic Myeloproliferative Disorders: A Population-Based Study from a Cancer Registry in Northern Italy.. <i>Blood</i> , 2007, 110, 4650-4650.	0.6	0
71	Secondary Malignancies after Treatment of Aggressive Non-Hodgkin Lymphoma: A GISL Cohort Study on 1259 Patients.. <i>Blood</i> , 2007, 110, 522-522.	0.6	0
72	The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. <i>European Journal of Haematology</i> , 2006, 76, 217-229.	1.1	8

#	ARTICLE	IF	CITATIONS
73	MOPPEBVCAD Chemotherapy with Limited and Conditioned Radiotherapy in Advanced Hodgkin's Lymphoma: 10-Year Results, Late Toxicity, and Second Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 529-535.	3.2	14
74	Bortezomib and Plasma Cell Leukemia.. <i>Blood</i> , 2006, 108, 3546-3546.	0.6	1
75	Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy.. <i>Blood</i> , 2006, 108, 2442-2442.	0.6	0
76	Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL.. <i>Blood</i> , 2006, 108, 2763-2763.	0.6	0
77	Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin's Lymphoma: A Multicenter Italian Experience. <i>Journal of Clinical Oncology</i> , 2005, 23, 468-473.	0.8	241
78	Future Directions in Haematology: Beyond Multiple Myeloma. <i>Acta Haematologica</i> , 2005, 114, 27-32.	0.7	1
79	Biological effects of ATRA and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts. <i>Leukemia and Lymphoma</i> , 2005, 46, 257-263.	0.6	1
80	PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study.. <i>Blood</i> , 2005, 106, 2600-2600.	0.6	5
81	Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw.. <i>Blood</i> , 2005, 106, 5057-5057.	0.6	20
82	Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas. <i>Cancer</i> , 2004, 101, 1601-1608.	2.0	40
83	Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results.. <i>Blood</i> , 2004, 104, 1523-1523.	0.6	4
84	Treatment of Indolent B-Cell Nonfollicular Lymphomas: Final Results of the LL01 Randomized Trial of the Gruppo Italiano per lo Studio dei Linfomi. <i>Journal of Clinical Oncology</i> , 2003, 21, 1459-1465.	0.8	23
85	Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia. <i>Leukemia</i> , 2002, 16, 955-956.	3.3	18
86	Bleomycin, Etoposide, Cyclophosphamide, Vincristine and Prednisone (BACOP) in Patients with Follicular Non-Hodgkin's Lymphoma: Results of a Prospective, Multicenter Study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL). <i>Leukemia and Lymphoma</i> , 2002, 43, 1795-1801.	0.6	6
87	Primary Systemic Anaplastic Large-Cell Lymphoma (CD30+): Advances in Biology and Current Therapeutic Approaches. <i>Clinical Lymphoma and Myeloma</i> , 2001, 2, 29-37.	2.1	18
88	Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 37, 13-25.	2.0	37
89	Persistent polyclonal B lymphocytosis: morphological, immunological, cytogenetic and molecular analysis of an Italian case. <i>Leukemia Research</i> , 2000, 24, 877-879.	0.4	4
90	Unexpected High Incidence of Severe Toxicities Associated with Alpha Interferon, Low-Dose Cytosine Arabinoside and All-Trans Retinoic Acid in Patients with Chronic Myelogenous Leukemia. <i>Leukemia and Lymphoma</i> , 1999, 35, 483-489.	0.6	13

#	ARTICLE	IF	CITATIONS
91	Chronic myelogenous leukemia in nonlymphoid blastic phase. , 1999, 86, 2632-2641.		167
92	Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. <i>Leukemia</i> , 1998, 12, 289-294.	3.3	19
93	All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. <i>Leukemia</i> , 1998, 12, 449-454.	3.3	13
94	Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling. <i>Clinical Drug Investigation</i> , 1998, 16, 25-33.	1.1	2
95	Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia.. <i>Journal of Clinical Oncology</i> , 1998, 16, 882-889.	0.8	15
96	Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia. <i>Leukemia</i> , 1997, 11, 1610-1616.	3.3	13
97	<i>In vivo</i> biological response following low-dose interleukin-2 in complete remission B-cell non-Hodgkin's lymphoma patients. <i>European Journal of Haematology</i> , 1996, 57, 33-37.	1.1	2
98	Detection of PML-RAR fusion transcript in Ph positive leukemia with acute promyelocytic phenotype lacking the t(15;17) cytogenetic abnormality. <i>Cancer Genetics and Cytogenetics</i> , 1995, 80, 95-99.	1.0	10
99	P-Glycoprotein Expression in Acute Myeloblasts Leukemia Analyzed by Immunocytochemistry and Flow Cytometry. <i>Leukemia and Lymphoma</i> , 1995, 17, 121-125.	0.6	8
100	The Role of α -Interferon in Essential Thrombocythaemia, Polycythaemia Vera and Myelofibrosis with Myeloid Metaplasia (MMM): A Concise Update. <i>Leukemia and Lymphoma</i> , 1995, 19, 13-20.	0.6	41
101	A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. <i>Annals of Hematology</i> , 1994, 68, 247-250.	0.8	43
102	Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. <i>British Journal of Haematology</i> , 1994, 86, 402-404.	1.2	50
103	Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term α -IFN treatment. <i>Annals of Hematology</i> , 1993, 66, 245-246.	0.8	16
104	Progression of Essential Thrombocythemia to Blastic Crisis Via Idiopathic Myelofibrosis. <i>Leukemia and Lymphoma</i> , 1993, 9, 423-426.	0.6	28
105	Kinetic and Immunophenotypic Heterogeneity in Acute Myeloid Leukemia Subpopulations. <i>Leukemia and Lymphoma</i> , 1992, 6, 161-166.	0.6	0
106	Sinus Histiocytosis with Massive Lymphadenopathy. <i>Leukemia and Lymphoma</i> , 1992, 7, 189-194.	0.6	15
107	The Use of the Alkaline Phosphatase-Antialkaline Phosphatase Technique for Immunophenotyping Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 1991, 85, 6-11.	0.7	2
108	Incidence of Lymphoid Markers in Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 1991, 86, 1-5.	0.7	3

#	ARTICLE	IF	CITATIONS
109	Interferon alpha-2b in the long-term treatment of essential thrombocythemia. <i>Annals of Hematology</i> , 1991, 63, 206-209.	0.8	25
110	Extramedullary Pleural Blast Crisis in Chronic Myelogenous Leukemia Cytogenetic and Molecular Study. <i>Acta Haematologica</i> , 1990, 83, 198-202.	0.7	8
111	Sinus histiocytosis with massive lymphadenopathy: Immunological, cytogenetic and molecular studies. <i>Blut</i> , 1990, 60, 339-344.	1.2	8
112	Acute nonlymphocytic leukemia with trisomy 4. <i>Cancer Genetics and Cytogenetics</i> , 1989, 41, 203-205.	1.0	10
113	Extremely low frequency pulsed electromagnetic fields increase cell proliferation in lymphocytes from young and aged subjects. <i>Biochemical and Biophysical Research Communications</i> , 1989, 160, 692-698.	1.0	132
114	Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki-67 and anti-bromo-deoxyuridine monoclonal antibodies. <i>British Journal of Haematology</i> , 1988, 69, 311-320.	1.2	44
115	PROMYELOCYTIC CRISIS OF CHRONIC MYELOID LEUKAEMIA. <i>British Journal of Haematology</i> , 1987, 66, 276-277.	1.2	3
116	Platelet alpha-granule release in chronic myeloproliferative disorders with thrombocytosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1986, 46, 163-166.	0.6	9
117	Platelet a granule release in diabetes mellitus. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1985, 45, 165-168.	0.6	18
118	Chromosomal abnormalities in essential thrombocythemia. <i>Cancer Genetics and Cytogenetics</i> , 1985, 18, 91-93.	1.0	11
119	LOW DOSE INTRAVENOUS PEPSIN-TREATED GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS. <i>British Journal of Haematology</i> , 1984, 58, 761-762.	1.2	8
120	A concise review of lenalidomide therapy for follicular lymphoma. <i>Expert Opinion on Orphan Drugs</i> , 0, , 1-7.	0.5	0